Products
Pre-made Radretumab benchmark antibody ( di-scFv + CH4, anti-FN extra domain B therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-464
Pre-Made Radretumab biosimilar, di-scFv + CH4: Anti-FN extra domain B therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Radretumab is an antineoplastic. Philogen, a pharmaceutical company specializing in antibody-drug conjugates, is developing it as a conjugate of Iodine-131 to an antibody which binds to fibronectin extra domain-B for treatment of Hodgkin lymphoma.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-ab-464-1mg | 1mg | Inquiry | ||
| GMP-Bios-ab-464-10mg | 10mg | Inquiry | ||
| GMP-Bios-ab-464-100mg | 100mg | Inquiry | ||
| GMP-Bios-ab-464-xmg | ＞100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Radretumab biosimilar, di-scFv + CH4: Anti-FN extra domain B therapeutic antibody |
| INN Name | Radretumab |
| Target | FN extra domain B |
| Format | di-scFv + CH4 |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgE |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2010 |
| Year Recommended | 2011 |
| Companies | Philogen |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Brain cancer;Non-small cell lung cancer;Solid tumours;Haematological malignancies;Hodgkin's disease |
| Development Tech | na |
<